Susquehanna International Group
FTH

Susquehanna International Group’s Faeth Therapeutics FTH Stock Holding History

Susquehanna International Group’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,903
Closed -$18.6K – 13388
2024
Q4 		$18.6K Sell
1,903
-2,618
-58% -$26.3K ﹤0.01% 11925
2024
Q3 		$54.1K Buy
+4,521
New +$55.2K ﹤0.01% 11351

Other funds holding FTH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return

Susquehanna International Group's FTH Position: Q1 2025 in Review

Susquehanna International Group sold out of Faeth Therapeutics (FTH) in Q1 2025, closing a stake of 1,903 shares — an estimated $18.6K sold.

Susquehanna International Group first reported a position in FTH in Q3 2024 and held it in 2 quarters. The position peaked at $54.1K in Q3 2024. 20 funds tracked by Wall St. Rank hold FTH as of Q1 2025.

  • Susquehanna International Group reported no remaining Faeth Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Susquehanna International Group sold 1,903 Faeth Therapeutics shares in Q1 2025, an estimated $18.6K.
  • Susquehanna International Group first reported a position in Faeth Therapeutics in Q3 2024 and held it in 2 quarters.
  • Susquehanna International Group's Faeth Therapeutics position peaked at $54.1K in Q3 2024.
  • 20 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q1 2025.

Based on Susquehanna International Group's 13F filing for Q1 2025, filed 14 May 2025.